A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Primary Purpose
Constipation
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
BLI-801
BLI-801
BLI-801
BLI-801
Sponsored by
About this trial
This is an interventional treatment trial for Constipation focused on measuring constipation, laxative
Eligibility Criteria
Inclusion Criteria:
- Male or female subjects at least 18 years of age
- Constipated according to ROME I criteria
- Otherwise in good health, as determined by physical exam and medical history
- If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
- Negative urine pregnancy test at screening, if applicable
- In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
Exclusion Criteria:
- Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
- Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study
- Subjects who are pregnant or lactating, or intending to become pregnant during the study
- Subjects of childbearing potential who refuse a pregnancy test
- Subjects who are allergic to any BLI-801 component.
- Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
- Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
Sites / Locations
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Experimental
Experimental
Experimental
Experimental
Arm Label
1
2
3
4
Arm Description
BLI-801 Dose 1
BLI-801 Dose 2
BLI-801 Dose 3
BLI-801 Dose 4
Outcomes
Primary Outcome Measures
Bowel Movement Count
Secondary Outcome Measures
Adverse events
Full Information
NCT ID
NCT00583154
First Posted
December 20, 2007
Last Updated
September 24, 2009
Sponsor
Braintree Laboratories
1. Study Identification
Unique Protocol Identification Number
NCT00583154
Brief Title
A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Official Title
A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
Study Type
Interventional
2. Study Status
Record Verification Date
September 2009
Overall Recruitment Status
Completed
Study Start Date
October 2007 (undefined)
Primary Completion Date
January 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Name of the Sponsor
Braintree Laboratories
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
To compare the safety and efficacy of BLI-801 administered at 4 dose levels in constipated adults.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Constipation
Keywords
constipation, laxative
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
60 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
1
Arm Type
Experimental
Arm Description
BLI-801 Dose 1
Arm Title
2
Arm Type
Experimental
Arm Description
BLI-801 Dose 2
Arm Title
3
Arm Type
Experimental
Arm Description
BLI-801 Dose 3
Arm Title
4
Arm Type
Experimental
Arm Description
BLI-801 Dose 4
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 1
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 2
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 3
Intervention Type
Drug
Intervention Name(s)
BLI-801
Intervention Description
Dose 4
Primary Outcome Measure Information:
Title
Bowel Movement Count
Time Frame
24 hours
Secondary Outcome Measure Information:
Title
Adverse events
Time Frame
24 hours
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Male or female subjects at least 18 years of age
Constipated according to ROME I criteria
Otherwise in good health, as determined by physical exam and medical history
If female, and of child-bearing potential, is using an acceptable form of birth control (hormonal birth control, IUD, double-barrier method, depot contraceptive, sterilized, abstinent, or vasectomized spouse)
Negative urine pregnancy test at screening, if applicable
In the Investigator's judgment, subject is mentally competent to provide informed consent to participate in the study
Exclusion Criteria:
Subjects with known or suspected ileus, gastrointestinal obstruction, gastric retention, bowel perforation, toxic colitis, toxic megacolon
Subjects taking laxatives or prokinetic agents that refuse to discontinue these treatments for the duration of the study
Subjects who are pregnant or lactating, or intending to become pregnant during the study
Subjects of childbearing potential who refuse a pregnancy test
Subjects who are allergic to any BLI-801 component.
Subjects who, in the opinion of the investigator, should not be included in the study for any reason, including inability to follow study procedures
Subjects who have participated in an investigational clinical, surgical, drug, or device study within the past 30 days
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
John McGowan
Organizational Affiliation
Braintree Laboratories, Inc.
Official's Role
Study Director
Facility Information:
City
Anaheim
State/Province
California
Country
United States
City
Cranston
State/Province
Rhode Island
Country
United States
City
Cumberland
State/Province
Rhode Island
Country
United States
12. IPD Sharing Statement
Learn more about this trial
A Pilot Efficacy Evaluation of BLI-801 as a Laxative in Constipated Adults
We'll reach out to this number within 24 hrs